A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2011
12/29/2011	US20110318351 Novel methods of cancer diagnosis and therapy targeted against a cancer stem line
12/29/2011	US20110318350 Antibodies that bind both il-17a and il-17f and methods of using the same
12/29/2011	US20110318349 Dual variable domain immunoglobulins and uses thereof
12/29/2011	US20110318348 Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc)
12/29/2011	US20110318347 Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin, beta1-integrin, human alpha2-integrin, cd81, sr-bi, claudin-1, claudin-6 and claudin-9, respectively, and neutralizing viral entry
12/29/2011	US20110318346 Alpha B-crystallin as a therapy for Ischemia or inflammation
12/29/2011	US20110318345 Nasal delivery
12/29/2011	US20110318344 Tumor Treatment
12/29/2011	US20110318343 Stable Liquid Pharmaceutical Formulation Of IgG Antibodies
12/29/2011	US20110318342 Methods of using il-1 antagonists to treat autoinflammatory disease
12/29/2011	US20110318341 Frizzled-binding agents and uses thereof
12/29/2011	US20110318340 Deglycosylated antibodies
12/29/2011	US20110318339 Anti-dll4 antibodies and uses thereof
12/29/2011	US20110318338 Targeting pax2 for the treatment of breast cancer
12/29/2011	US20110318337 Humaneered anti-factor b antibody
12/29/2011	US20110318336 Identification and Treatment of Aggressive Lung Cancer Tumors
12/29/2011	US20110318335 Methods and products for treating proliferative diseases
12/29/2011	US20110318334 Taxane analogs for the treatment of brain cancer
12/29/2011	US20110318333 Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease
12/29/2011	US20110318332 Immunoglobulin g composition
12/29/2011	US20110318306 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
12/29/2011	US20110318305 Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
12/29/2011	US20110318304 Detection of epha3 as a marker of the presence of a solid tumor
12/29/2011	US20110318302 Cancer Treatment
12/29/2011	US20110318301 Il-17a/f heterologous polypeptides and therapeutic uses thereof
12/29/2011	US20110318274 Variant of mite allergen and uses thereof
12/29/2011	US20110318269 Method For Screening Phage Display Libraries Against Each Other
12/29/2011	US20110318265 Coupled identification and treatment of cancer
12/29/2011	US20110318264 Methods and compositions for diagnosis and treatment of cancer
12/29/2011	CA2803588A1 Antibodies to the c3d fragment of complement component 3
12/29/2011	CA2803392A1 Dual variable domain immunoglobulins and uses thereof
12/29/2011	CA2803391A1 Colon and pancreas cancer specific antigens and antibodies
12/29/2011	CA2803239A1 Combinations of meningococcal factor h binding proteins
12/29/2011	CA2803175A1 Means of controlling infection persistence of helicobacter pylori
12/29/2011	CA2803058A1 Homodimeric protein constructs
12/29/2011	CA2803029A1 Constrained immunogenic compositions and uses therefor
12/28/2011	EP2400021A2 ErbB3 based methods and compositions for treating neoplasms
12/28/2011	EP2400019A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400018A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400017A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400016A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400015A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400014A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400013A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400012A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400011A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400010A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400009A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400008A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400007A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400006A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400005A2 In tumours differentially expressed gene products and use of the same
12/28/2011	EP2400004A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2400003A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2400002A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2400001A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2400000A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399999A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399998A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399997A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399996A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399995A2 In tumours differentially expressed gene products and use of the same.
12/28/2011	EP2399937A1 Anti-human alpha9 integrin antibody and use thereof
12/28/2011	EP2399936A2 Anti-CD154 antibodies
12/28/2011	EP2399935A2 An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
12/28/2011	EP2399605A1 Extending time to disease progression or survival in cancer patients
12/28/2011	EP2399604A1 Novel antibody formulation
12/28/2011	EP2399602A1 HIV-1 Clade A consensus sequences, antigens, and transgenes
12/28/2011	EP2399595A1 Immunopotentiating composition and process for producing same
12/28/2011	EP2399586A1 Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
12/28/2011	EP2399135A2 Method for inhibiting neurodegeneration
12/28/2011	EP2398902A1 Methods and compositions for diagnosis and treatment of cancer
12/28/2011	EP2398892A1 Live attenuated vaccines
12/28/2011	EP2398828A2 Specific binding proteins and uses thereof
12/28/2011	EP2398827A2 Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists
12/28/2011	EP2398823A1 Monoclonal antibodies against vaginolysin
12/28/2011	EP2398821A1 Inactivated dengue virus vaccine with aluminium-free adjuvant
12/28/2011	EP2398498A2 Antibody molecules having specificity for human ox40
12/28/2011	EP2398497A1 Methods and compositions for diagnosis and treatment of cancer
12/28/2011	EP2398496A2 Vesicular stomatitis virus vectors encoding hiv env epitopes
12/28/2011	EP2398494A2 Proproteins and methods of use thereof
12/28/2011	EP2386577A9 Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
12/28/2011	EP1917977B1 Therapeutic drug for heart disease and virus disease
12/28/2011	EP1871391B1 Endogenous retrovirus and proteins encoded by env as a target for cancer treatment
12/28/2011	EP1851320B1 Vaccines based on the use of mva
12/28/2011	EP1667716B1 Cytotoxicity mediation of cells evidencing surface expression of cd44
12/28/2011	EP1644037B1 Functional influenza virus-like particles (vlps)
12/28/2011	EP1640458B1 Method of selecting patients suitable for wt1 vaccine
12/28/2011	EP1599221B1 Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
12/28/2011	EP1490100B1 Combined dna/protein vaccine compositions
12/28/2011	CN1938044B 用于免疫治疗的基于酵母的疫苗 Yeast-based vaccines for immunotherapy
12/28/2011	CN1774259B 治疗系统性红斑狼疮的肽的胃肠道外制剂 Parenteral preparations for treatment of systemic lupus erythematosus peptides
12/28/2011	CN102300879A 双重可变结构域免疫球蛋白及其用途 Dual variable domain immunoglobulins and their use
12/28/2011	CN102300872A 猿腺病毒核酸和氨基酸序列，包含其的载体及其用途 Simian adenovirus nucleic acid and amino acid sequences, including its carrier and its use
12/28/2011	CN102300586A 稳定的药物组合物，其含有至少一种单克隆抗体和至少一种包含疏水性取代基的两亲性多糖 Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one substituent comprising a hydrophobic amphipathic polysaccharide
12/28/2011	CN102300585A 包含血红蛋白受体的脑膜炎球菌疫苗 Meningococcal vaccine comprising the hemoglobin receptor
12/28/2011	CN102300584A 可注射的肉毒杆菌毒素制剂 Injectable botulinum toxin preparations
12/28/2011	CN102300583A Goodpasture抗原结合蛋白及其检测 Goodpasture antigen binding protein and its detection
12/28/2011	CN102300556A 含有阴离子药物的药物组合物及其制备方法 Pharmaceutical compositions containing an anionic drug and preparation method
12/28/2011	CN102296089A 高效制备猪圆环病毒2型空衣壳粒子的方法 Efficient methods for preparing porcine circovirus type 2 empty capsid particles

1 ... 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 ... 1823